154 related articles for article (PubMed ID: 19148555)
1. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy.
Boidot R; Vegran F; Lizard-Nacol S
Int J Mol Med; 2009 Feb; 23(2):285-91. PubMed ID: 19148555
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.
Végran F; Boidot R; Oudin C; Riedinger JM; Bonnetain F; Lizard-Nacol S
Clin Cancer Res; 2006 Oct; 12(19):5794-800. PubMed ID: 17020986
[TBL] [Abstract][Full Text] [Related]
3. Distinct expression of Survivin splice variants in breast carcinomas.
Vegran F; Boidot R; Oudin C; Riedinger JM; Lizard-Nacol S
Int J Oncol; 2005 Oct; 27(4):1151-7. PubMed ID: 16142334
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma.
Végran F; Boidot R; Bonnetain F; Cadouot M; Chevrier S; Lizard-Nacol S
Endocr Relat Cancer; 2011 Dec; 18(6):783-92. PubMed ID: 21878572
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
[TBL] [Abstract][Full Text] [Related]
6. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer.
Végran F; Boidot R; Oudin C; Defrain C; Rebucci M; Lizard-Nacol S
Oncogene; 2007 Jan; 26(2):290-7. PubMed ID: 16847456
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer.
Atlasi Y; Mowla SJ; Ziaee SA
Cancer Detect Prev; 2009; 32(4):308-13. PubMed ID: 19186007
[TBL] [Abstract][Full Text] [Related]
8. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
[TBL] [Abstract][Full Text] [Related]
9. Survivin expression predicts early recurrence in early-stage breast cancer.
Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K
Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
[TBL] [Abstract][Full Text] [Related]
11. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas.
Suga K; Yamamoto T; Yamada Y; Miyatake S; Nakagawa T; Tanigawa N
Oncol Rep; 2005 May; 13(5):891-7. PubMed ID: 15809755
[TBL] [Abstract][Full Text] [Related]
12. High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer.
Span PN; Tjan-Heijnen VC; Manders P; van Tienoven D; Lehr J; Sweep FC
Breast Cancer Res Treat; 2006 Jul; 98(2):223-30. PubMed ID: 16541327
[TBL] [Abstract][Full Text] [Related]
13. Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis.
Vallböhmer D; Drebber U; Schneider PM; Baldus S; Bollschweiler E; Brabender J; Warnecke-Eberz U; Mönig S; Hölscher AH; Metzger R
J Surg Oncol; 2009 Jun; 99(7):409-13. PubMed ID: 19347901
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance and different properties of survivin splicing variants in gastric cancer.
Meng H; Lu C; Mabuchi H; Tanigawa N
Cancer Lett; 2004 Dec; 216(2):147-55. PubMed ID: 15533590
[TBL] [Abstract][Full Text] [Related]
15. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
Schrohl AS; Meijer-van Gelder ME; Holten-Andersen MN; Christensen IJ; Look MP; Mouridsen HT; Brünner N; Foekens JA
Clin Cancer Res; 2006 Dec; 12(23):7054-8. PubMed ID: 17114213
[TBL] [Abstract][Full Text] [Related]
16. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
[TBL] [Abstract][Full Text] [Related]
17. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
18. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties.
Mahotka C; Wenzel M; Springer E; Gabbert HE; Gerharz CD
Cancer Res; 1999 Dec; 59(24):6097-102. PubMed ID: 10626797
[TBL] [Abstract][Full Text] [Related]
19. Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
Moriai R; Tsuji N; Moriai M; Kobayashi D; Watanabe N
Breast Cancer Res Treat; 2009 Sep; 117(2):261-71. PubMed ID: 18815881
[TBL] [Abstract][Full Text] [Related]
20. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression.
Krieg A; Mahotka C; Krieg T; Grabsch H; Müller W; Takeno S; Suschek CV; Heydthausen M; Gabbert HE; Gerharz CD
Br J Cancer; 2002 Mar; 86(5):737-43. PubMed ID: 11875736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
